Esperion Therapeutics Inc (NASDAQ:ESPR) has a beta value of 0.82 and has seen 2.57 million shares traded in the recent trading session. The company, currently valued at $304.69M, closed the recent trade at $1.54 per share which meant it lost -$0.04 on the day or -2.53% during that session. The ESPR stock price is -155.84% off its 52-week high price of $3.94 and -1.3% below the 52-week low of $1.56.
The consensus among analysts is that Esperion Therapeutics Inc (ESPR) is Buy stock at the moment, with a recommendation rating of 1.78. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.18.
Esperion Therapeutics Inc (NASDAQ:ESPR) trade information
Sporting -2.53% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ESPR stock price touched $1.54 or saw a rise of 14.44%. Year-to-date, Esperion Therapeutics Inc shares have moved -30.00%, while the 5-day performance has seen it change -12.99%. Over the past 30 days, the shares of Esperion Therapeutics Inc (NASDAQ:ESPR) have changed -17.20%.
Wall Street analysts have a consensus price target for the stock at $8, which means that the shares’ value could jump 80.75% from the levels at last check today. The projected low price target is $8.0 while the price target rests at a high of $8.0. In that case, then, we find that the latest price level in today’s session is -419.48% off the targeted high while a plunge would see the stock gain -419.48% from the levels at last check today.
Esperion Therapeutics Inc (ESPR) estimates and forecasts
The company’s shares have lost -6.67% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 4.87%.
6 analysts offering their estimates for the company have set an average revenue estimate of 54.97M for the current quarter. 6 have an estimated revenue figure of 61.74M for the next ending quarter. Year-ago sales stood 137.74M and 73.83M respectively for this quarter and the next, and analysts expect sales will shrink by -60.09% for the current quarter and 4.87% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 40.11% over the past 5 years.
ESPR Dividends
Esperion Therapeutics Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Esperion Therapeutics Inc (NASDAQ:ESPR)’s Major holders
The top two institutional holders are WASATCH ADVISORS LP with over 16.86 million shares worth more than $37.44 million. As of 2024-06-30, WASATCH ADVISORS LP held 8.9319% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 13.98 million shares as of 2024-06-30. The firm’s total holdings are worth over $31.04 million and represent 8.2617% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund. As of Dec 31, 2024, the former fund manager holds about 3.39% shares in the company for having 6.68 shares of worth $10.33 million while later fund manager owns 6.18 shares of worth $9.56 million as of Dec 31, 2024, which makes it owner of about 3.14% of company’s outstanding stock.
